{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T23:14:49Z","timestamp":1789168489193,"version":"build-2803163510"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"8108","license":[{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2026,4,2]]},"DOI":"10.1038\/s41586-025-10031-z","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T16:02:35Z","timestamp":1765987355000},"page":"181-188","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes"],"prefix":"10.1038","volume":"652","author":[{"given":"Lixin","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3060-7850","authenticated-orcid":false,"given":"Bo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanqing","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhifeng","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suhe","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianlin","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yushan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanbo","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6058-267X","authenticated-orcid":false,"given":"Haiwei","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Han-Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengtai","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8720-7140","authenticated-orcid":false,"given":"Lei","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenying","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the DREAMS-2 investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"key":"10031_CR1","doi-asserted-by":"publisher","first-page":"160","DOI":"10.2337\/dc23-1287","volume":"47","author":"B Zhang","year":"2024","unstructured":"Zhang, B. et al. Efficacy and safety of mazdutide in Chinese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 2 trial. Diabetes Care 47, 160\u2013168 (2024).","journal-title":"Diabetes Care"},{"key":"10031_CR2","doi-asserted-by":"publisher","first-page":"e1098","DOI":"10.1016\/S2468-2667(24)00251-2","volume":"9","author":"Y Xu","year":"2024","unstructured":"Xu, Y. et al. Diabetes in China part 2: prevention, challenges, and progress. Lancet Public Health 9, e1098\u2013e1104 (2024).","journal-title":"Lancet Public Health"},{"key":"10031_CR3","doi-asserted-by":"publisher","unstructured":"Chinese Diabetes Society. Guideline for the prevention and treatment of diabetes mellitus in China (2024 edition). Chin. J. Diabetes https:\/\/doi.org\/10.3760\/cma.j.cn115791-20241203-00705 (2025).","DOI":"10.3760\/cma.j.cn115791-20241203-00705"},{"key":"10031_CR4","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1016\/S0140-6736(22)01655-5","volume":"400","author":"E Ahmad","year":"2022","unstructured":"Ahmad, E., Lim, S., Lamptey, R., Webb, D. R. & Davies, M. J. Type 2 diabetes. Lancet 400, 1803\u20131820 (2022).","journal-title":"Lancet"},{"key":"10031_CR5","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S2213-8587(21)00113-3","volume":"9","author":"MA Nauck","year":"2021","unstructured":"Nauck, M. A., Wefers, J. & Meier, J. J. Treatment of type 2 diabetes: challenges, hopes, and anticipated successes. Lancet Diabetes Endocrinol. 9, 525\u2013544 (2021).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10031_CR6","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/S0140-6736(21)01919-X","volume":"399","author":"I Lingvay","year":"2022","unstructured":"Lingvay, I., Sumithran, P., Cohen, R. V. & le Roux, C. W. Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation. Lancet 399, 394\u2013405 (2022).","journal-title":"Lancet"},{"key":"10031_CR7","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.2337\/dci22-0034","volume":"45","author":"MJ Davies","year":"2022","unstructured":"Davies, M. J. et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 45, 2753\u20132786 (2022).","journal-title":"Diabetes Care"},{"key":"10031_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-13-602","volume":"13","author":"L-N Ji","year":"2013","unstructured":"Ji, L.-N. et al. Glycemic control among patients in China with type 2 diabetes mellitus receiving oral drugs or injectables. BMC Public Health 13, 602 (2013).","journal-title":"BMC Public Health"},{"key":"10031_CR9","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S2213-8587(17)30013-X","volume":"5","author":"C Sorli","year":"2017","unstructured":"Sorli, C. et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 5, 251\u2013260 (2017).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10031_CR10","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","volume":"398","author":"J Rosenstock","year":"2021","unstructured":"Rosenstock, J. et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet 398, 143\u2013155 (2021).","journal-title":"Lancet"},{"key":"10031_CR11","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","volume":"9","author":"N Sattar","year":"2021","unstructured":"Sattar, N. et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 9, 653\u2013662 (2021).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10031_CR12","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic, V. et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N. Engl. J. Med. 391, 109\u2013121 (2024).","journal-title":"N. Engl. J. Med."},{"key":"10031_CR13","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.2337\/dci24-0003","volume":"47","author":"DJ Drucker","year":"2024","unstructured":"Drucker, D. J. Efficacy and safety of GLP-1 medicines for type 2 diabetes and obesity. Diabetes Care 47, 1873\u20131888 (2024).","journal-title":"Diabetes Care"},{"key":"10031_CR14","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1007\/s00125-023-06053-9","volume":"67","author":"M Bl\u00fcher","year":"2024","unstructured":"Bl\u00fcher, M., Rosenstock, J., Hoefler, J., Manuel, R. & Hennige, A. M. Dose\u2013response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon\/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial. Diabetologia 67, 470\u2013482 (2024).","journal-title":"Diabetologia"},{"key":"10031_CR15","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/S0140-6736(23)01053-X","volume":"402","author":"J Rosenstock","year":"2023","unstructured":"Rosenstock, J. et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet 402, 529\u2013544 (2023).","journal-title":"Lancet"},{"key":"10031_CR16","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.2337\/dc20-2151","volume":"44","author":"R Nahra","year":"2021","unstructured":"Nahra, R. et al. Effects of cotadutide on metabolic and hepatic parameters in adults with overweight or obesity and type 2 diabetes: a 54-week randomized phase 2b study. Diabetes Care 44, 1433\u20131442 (2021).","journal-title":"Diabetes Care"},{"key":"10031_CR17","doi-asserted-by":"publisher","first-page":"e12432","DOI":"10.1111\/cob.12432","volume":"11","author":"M Alba","year":"2021","unstructured":"Alba, M., Yee, J., Frustaci, M. E., Samtani, M. N. & Fleck, P. Efficacy and safety of glucagon-like peptide-1\/glucagon receptor co-agonist JNJ-64565111 in individuals with obesity without type 2 diabetes mellitus: a randomized dose-ranging study. Clin. Obes. 11, e12432 (2021).","journal-title":"Clin. Obes."},{"key":"10031_CR18","doi-asserted-by":"publisher","first-page":"3390","DOI":"10.1111\/dom.15238","volume":"25","author":"K Chen","year":"2023","unstructured":"Chen, K. et al. Prevalence of obesity and associated complications in China: a cross-sectional, real-world study in 15.8 million adults. Diabetes Obes. Metab. 25, 3390\u20133399 (2023).","journal-title":"Diabetes Obes. Metab."},{"key":"10031_CR19","doi-asserted-by":"publisher","first-page":"S167","DOI":"10.2337\/dc25-S008","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","unstructured":"American Diabetes Association Professional Practice Committee. Obesity and weight management for the prevention and treatment of type 2 diabetes: standards of care in diabetes\u20132025. Diabetes Care 48, S167\u2013S180 (2025).","journal-title":"Diabetes Care"},{"key":"10031_CR20","doi-asserted-by":"publisher","first-page":"154218","DOI":"10.1016\/j.metabol.2020.154218","volume":"107","author":"N Katsiki","year":"2020","unstructured":"Katsiki, N., Ferrannini, E. & Mantzoros, C. New American Diabetes Association (ADA)\/European Association for the Study of Diabetes (EASD) guidelines for the pharmacotherapy of type 2 diabetes: placing them into a practicing physician\u2019s perspective. Metabolism 107, 154218 (2020).","journal-title":"Metabolism"},{"key":"10031_CR21","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1111\/dom.13506","volume":"21","author":"W Wang","year":"2019","unstructured":"Wang, W. et al. Efficacy and safety of once-weekly dulaglutide versus insulin glargine in mainly Asian patients with type 2 diabetes mellitus on metformin and\/or a sulphonylurea: a 52-week open-label, randomized phase III trial. Diabetes Obes. Metab. 21, 234\u2013243 (2019).","journal-title":"Diabetes Obes. Metab."},{"key":"10031_CR22","doi-asserted-by":"publisher","DOI":"10.2337\/db23-778-P","volume":"72","author":"D ANWAR","year":"2023","unstructured":"Anwar, D. et al. Efficacy and safety of supaglutide as add-on to metformin in patients with type 2 diabetes. Diabetes 72, 778-P (2023).","journal-title":"Diabetes"},{"key":"10031_CR23","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1111\/dom.14232","volume":"23","author":"L Ji","year":"2021","unstructured":"Ji, L. et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes in SUSTAIN China: a 30-week, double-blind, phase 3a, randomized trial. Diabetes Obes. Metab. 23, 404\u2013414 (2021).","journal-title":"Diabetes Obes. Metab."},{"key":"10031_CR24","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S2213-8587(17)30092-X","volume":"5","author":"B Ahr\u00e9n","year":"2017","unstructured":"Ahr\u00e9n, B. et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. Lancet Diabetes Endocrinol. 5, 341\u2013354 (2017).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10031_CR25","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.regpep.2006.12.016","volume":"141","author":"P Schlatter","year":"2007","unstructured":"Schlatter, P., Beglinger, C., Drewe, J. & Gutmann, H. Glucagon-like peptide 1 receptor expression in primary porcine proximal tubular cells. Regul. Pept. 141, 120\u2013128 (2007).","journal-title":"Regul. Pept."},{"key":"10031_CR26","doi-asserted-by":"publisher","first-page":"F469","DOI":"10.1152\/ajprenal.00560.2015","volume":"311","author":"L Bankir","year":"2016","unstructured":"Bankir, L., Bouby, N., Blondeau, B. & Crambert, G. Glucagon actions on the kidney revisited: possible role in potassium homeostasis. Am. J. Physiol. Renal Physiol. 311, F469\u2013F486 (2016).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"10031_CR27","doi-asserted-by":"publisher","first-page":"19619","DOI":"10.1073\/pnas.1908706116","volume":"116","author":"PC Wilson","year":"2019","unstructured":"Wilson, P. C. et al. The single-cell transcriptomic landscape of early human diabetic nephropathy. Proc. Natl Acad. Sci. USA 116, 19619\u201319625 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"10031_CR28","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.kint.2024.08.023","volume":"106","author":"V Selvarajah","year":"2024","unstructured":"Selvarajah, V. et al. A randomized phase 2b trial examined the effects of the glucagon-like peptide-1 and glucagon receptor agonist cotadutide on kidney outcomes in patients with diabetic kidney disease. Kidney Int. 106, 1170\u20131180 (2024).","journal-title":"Kidney Int."},{"key":"10031_CR29","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1111\/dom.13340","volume":"20","author":"YH Chen","year":"2018","unstructured":"Chen, Y. H. et al. Efficacy and safety of dulaglutide monotherapy compared with glimepiride in East-Asian patients with type 2 diabetes in a multicentre, double-blind, randomized, parallel-arm, active comparator, phase III trial. Diabetes Obes. Metab. 20, 2121\u20132130 (2018).","journal-title":"Diabetes Obes. Metab."},{"key":"10031_CR30","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.diabet.2019.101117","volume":"46","author":"M Capehorn","year":"2020","unstructured":"Capehorn, M. et al. Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1\u20133 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). Diabetes Metab. 46, 100\u2013109 (2020).","journal-title":"Diabetes Metab."},{"key":"10031_CR31","doi-asserted-by":"publisher","first-page":"S83","DOI":"10.2337\/dc22-S006","volume":"45","author":"American Diabetes Association Professional Practice Committee.","year":"2022","unstructured":"American Diabetes Association Professional Practice Committee. Glycemic targets: standards of medical care in diabetes\u20142022. Diabetes Care 45, S83\u2013S96 (2022).","journal-title":"Diabetes Care"},{"key":"10031_CR32","unstructured":"Food and Drug Administration. Multiple Endpoints in Clinical Trials: Guidance for Industry. Report No. FDA-2016-D-4460 (FDA, 2022)."},{"key":"10031_CR33","unstructured":"ICH. ICH Harmonised Guideline: Addendum on estimands and sensitivity analysis in clinical trials. ICH E9(R1) (ICH, 2019)."}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41586-025-10031-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-025-10031-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-025-10031-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T11:07:23Z","timestamp":1775041643000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41586-025-10031-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,17]]},"references-count":33,"journal-issue":{"issue":"8108","published-print":{"date-parts":[[2026,4,2]]}},"alternative-id":["10031"],"URL":"https:\/\/doi.org\/10.1038\/s41586-025-10031-z","relation":{},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,17]]},"assertion":[{"value":"16 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H.C. and H.J. serve as consultants to Innovent Biologics. H.H., Q.M., L.L., H.\u00a0Du, H.H.-Z., F.X., H.\u00a0Deng and L.Q. are employees of Innovent Biologics. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}